|Primary Industry:||Pharma & Biotech|
|Executive Summary:||Argentum Medica, a spin-off of Aphios Corporation, is a nanotechnology company focused on developing oral bioavailable therapeutic peptides and proteins. Aphios Corporation, based in Woburn, MA, USA, is developing enabling technology platforms for improving the discovery, manufacturing, delivery and pathogenic safety of therapeutic drugs.
Argentum plans to enhance the oral bioavailability of therapeutic proteins by encapsulating protein nanoparticles in biodegradable polymer nanospheres. Nanoencapsulation will be used to protect the protein nanoparticles during the stomach passage; the residence time in the stomach will be short compared to the protein release rate from the polymer nanospheres. We have preliminary data that demonstrates that insulin, a labile peptide, being nanoencapsulated was protected in the stomach and then transported to the blood. When prodrug nanoparticles reach the gut, they can be transported across the lining, which may be mediated by M cells in the lymphatic tissue of the gut. Alternatively, the protein can be mobilized from nanoparticles and rapidly transported to systemic circulation by the epithelial cells. We believe that our oral delivery nanotechnology will be applicable to large as well small protein molecules since we have demonstrated that our protein nanoparticles technology is independent of size and molecular weight (MW).